Italia markets closed

Valneva SE (VLA.PA)

Paris - Paris Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
5,71-0,05 (-0,83%)
Alla chiusura: 05:36PM CEST
Schermo intero
Chiusura precedente5,76
Aperto5,85
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno5,54 - 5,99
Intervallo di 52 settimane4,95 - 29,70
Volume667.897
Media Volume517.559
Capitalizzazione789,438M
Beta (5 anni mensile)0,94
Rapporto PE (ttm)N/D
EPS (ttm)-0,71
Prossima data utili10 nov 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1A11,50
  • GlobeNewswire

    Valneva Announces Closing of Upsized €102.9 Million Global Offering

    The financing was led by US healthcare specialist Deep Track Capital and also included existing shareholders such as French state-owned bank BpifranceProceeds to be primarily used to continue to advance both the Company’s Phase 3 Lyme disease and chikungunya vaccine candidates towards marketing approval and to progress preclinical assets Saint Herblain (France), October 4, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (the “Company”), a specialty vaccine company, announced today the clos

  • GlobeNewswire

    Valneva Announces Pricing of €102.9 Million Global Offering of American Depositary Shares and Ordinary Shares

    Saint Herblain (France), September 30, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (the “Company”), a specialty vaccine company, announced today the pricing of 21,000,000 ordinary shares in a global offering to specified categories of investors comprised of a public offering of 375,000 American Depositary Shares (“ADSs”), each representing two ordinary shares, in the United States (the “U.S. Offering”) and a concurrent private placement of 20,250,000 ordinary shares in certain jurisdic

  • GlobeNewswire

    Valneva Announces Launch of Approximately $40 Million in a Proposed Global Offering of American Depositary Shares and Ordinary Shares

    Saint Herblain (France), September 28, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (the “Company”), a specialty vaccine company, today announced its intention to issue and sell, subject to market conditions, approximately $40 million of its ordinary shares in a global offering to specified categories of investors comprised of (i) a public offering of its American Depositary Shares (“ADSs”), each representing two ordinary shares, in the United States (the “U.S. Offering”) and (ii) a con